Cargando…
Screening and Targeting Risk Factors for Prodromal Synucleinopathy: Taking Steps toward a Prescriptive Multi-modal Framework
As the prevalence of Parkinson’s disease (PD) grows, so too does the population at-risk of developing PD, those in the so-called prodromal period. This period can span from those experiencing subtle motor deficits yet not meeting full diagnostic criteria or those with physiologic markers of disease...
Autores principales: | Neilson, Lee E, Quinn, Joseph F, Lim, Miranda M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JKL International LLC
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389816/ https://www.ncbi.nlm.nih.gov/pubmed/37307836 http://dx.doi.org/10.14336/AD.2022.1024 |
Ejemplares similares
-
Baseline characteristics of the North American prodromal Synucleinopathy cohort
por: Elliott, Jonathan E., et al.
Publicado: (2023) -
Stratification Tools for Disease‐Modifying Trials in Prodromal Synucleinopathy
por: Arnaldi, Dario, et al.
Publicado: (2021) -
Neuroinflammation and Immune Changes in Prodromal Parkinson’s Disease and Other Synucleinopathies
por: Terkelsen, Miriam Højholt, et al.
Publicado: (2022) -
Mitochondrial function-associated genes underlie cortical atrophy in prodromal synucleinopathies
por: Rahayel, Shady, et al.
Publicado: (2023) -
Racial Differences in Trust and Risk Disclosure Preferences Among Older
Registered Research Volunteers Screened for Prodromal Synucleinopathies
por: Marshall, Carly, et al.
Publicado: (2022)